Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hemostemix Inc (OP: HMTXF )

0.0470 -0.0045 (-8.74%)
Streaming Delayed Price Updated: 9:31 AM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,000
Open 0.0515
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0515
Today's Range 0.0470 - 0.0470
52wk Range 0.0240 - 0.0860
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")... 
Via Newsfile

Performance

YTD
-15.62%
-15.62%
1 Month
-7.84%
-7.84%
3 Month
+42.42%
+42.42%
6 Month
+26.68%
+26.68%
1 Year
-40.51%
-40.51%

More News

Read More
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Via Newsfile
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Via Newsfile
Hemostemix Announces Its Presentation to the Emerging Growth Conference
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Via Newsfile
Hemostemix Announces Closing of $2,750,000
Via IssueWire
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
Via IssueWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Your Fountain of Youth Trademarked by Hemostemix Inc.
Via IssueWire
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Announces Closing of UNIT Private Placement
Via IssueWire
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Via Benzinga
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Peter Lacey Increases His Investment in Hemostemix Inc.
Via Newsfile
Topics Intellectual Property
Exposures Intellectual Property
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
Via Newsfile
Topics Economy Intellectual Property
Exposures COVID-19 Economy Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.